Novartis AG (Novartis) specializes in the research, development, manufacturing, and marketing of a range of healthcare products led by pharmaceuticals, including eye care products.
Novartis ardently pursues measures to reduce its environmental impacts, both in terms of climate change and toxic emissions mitigation. First and foremost, a majority of the company’s facilities are certified to the ISO 14001 international environmental management system, and the company lists goals and initiatives to further improve its production processes. Moreover, Novartis goes above and beyond by implementing a range of policies and initiatives to ensure that environmental concerns remain paramount, including: carrying out product lifecycle assessments; creating a Green Chemistry Scorecard; conducting solvent assessments; and proactively putting a price on carbon internally.
Despite utilizing certain best practices regarding product quality and anti-corruption, Novartis continues to face repeated regulatory warnings and bribery allegations, demonstrating a need for more robust management systems.
Industry: Health Care
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 12/31/16 and may not reflect current opinions or subsequent events.